18 completed, 3 unknown, 2 withdrawn, 1 recruiting. 25 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 18, Unknown 3, Withdrawn 2, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Risk-Taking: new trials by email Literature Review of Risk-Taking trials Research Report on Risk-Taking
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate), Psychotherapy assisted by low-dose psilocybin (1 mg) - Gambling Disorder | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2026-10-08 | 2026-10-16 |
| RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response Naltrexone, Placebo - Eye Tracking, Gambling Disorder | Phase 2 | Unknown | University of Sao Paulo | 40 | 2021-06-01 | 2021-02-04 |
| Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder Naloxone hydrochloride, Placebo - Pathological Gambling, Gambling Disorder | Phase 2 | Unknown | Finnish Institute for Health and Welfare | 126 | 2018-02-22 | 2019-07-16 |
| Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Naloxone hydrochloride 20mg/ml - Gambling, Opioid | Phase 2 | Completed | Finnish Institute for Health and Welfare | 20 | 2017-02-14 | 2019-09-12 |
| Pro-Change Population Health Solution PCPHC, Usual care - Risk Behavior | Phase 2 | Unknown | Pro-Change Behavior Systems | 780 | 2016-05-01 | 2016-06-02 |
| BEing Safe in Treatment BEST assessment only, BEST assessment plus feedback report, Standard Counselor Training - Risk Behavior, Sex, Unsafe | Phase 2 | Completed | University of Washington | 537 | 2015-06-01 | 2018-07-02 |
| Milk Thistle in Pathological Gambling Placebo, Milk Thistle - Pathological Gambling, Gambling Disorder | Phase 2 | Completed | University of Chicago | 55 | 2015-01-01 | 2026-07-07 |
| XY-Zone Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Youth XY-Zone - Adolescent Problem Behavior at School, Risk Behavior | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 91 | 2011-08-01 | 2013-07-10 |
| Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling CRAFT treatment, Treatment as Usual - Pathological Gambling | Phase 2 | Withdrawn | Colchester East Hants Health Authority | 2011-06-03 | 2020-01-23 | |
| Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial Family Therapy based on Structural Family Therapy, Group Therapy, Psychoeducational Sessions - Substance Use Disorders, Risk Behavior | Phase 2 | Completed | University of Miami | 190 | 2011-01-01 | 2015-12-16 |
| Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Ecopipam - Pathological Gambling | Phase 2 | Completed | Emalex Biosciences Inc. | 34 | 2010-10-01 | 2024-05-14 |
| N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers N Acetyl Cysteine, Sugar Pill - Gambling, Tobacco Use Disorder | Phase 2 | Completed | University of Chicago | 28 | 2009-09-01 | 2023-03-21 |
| D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Haloperidol, Fluphenazine, Dexedrine - Pathological Gambling | Phase 2 | Completed | Centre for Addiction and Mental Health | 60 | 2009-09-01 | 2016-04-25 |
| Tolcapone Treatment of Pathological Gambling Tolcapone - Pathological Gambling | Phase 2 | Completed | University of Chicago | 24 | 2009-06-01 | 2023-02-23 |
| Topiramate Trial for Pathological Gamblers Topiramate flexible dosage, Placebo matching tablets, 4-session gambling cognitive restructuring - Pathological Gambling | Phase 2 | Completed | University of Sao Paulo | 38 | 2009-06-01 | 2013-05-03 |
| Investigation of Naltrexone for Pathological Gambling Naltrexone, Placebo - Pathological Gambling | Phase 2 | Completed | Yale University | 9 | 2009-02-01 | 2017-10-13 |
| Memantine Treatment Study of Pathological Gambling Memantine Hydrochloride - Pathological Gambling | Phase 2 | Completed | Yale University | 29 | 2007-12-01 | 2013-04-08 |
| Topiramate on Gambling-Related Behaviours Topiramate - Gambling | Phase 2 | Withdrawn | Centre for Addiction and Mental Health | 2006-09-01 | 2015-07-22 | |
| Cognitive Behavioral Therapy for Pathological Gambling Cognitive Behavioral Therapy, Wait-list - Pathological Gambling | Phase 2 | Completed | University of Minnesota | 76 | 2006-06-01 | 2010-01-05 |
| Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women Healthy Love Workshop, HIV/AIDS 101 Workshop - HIV Infections, Sexually Transmitted Infections | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 313 | 2006-05-01 | 2010-05-14 |
Showing 20 of 25. Sign in to see all of them.
Gambling (18) · Safe Sex (3) · Sexual Behavior (3) · HIV Infections (2) · Sexually Transmitted Diseases (2) · Substance-Related Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Behavior, Addictive (1) · Homosexuality, Male (1) · Mental Disorders (1) · Patient Participation (1) · Risk Reduction Behavior (1) · Tobacco Use Disorder (1)
Behavior (25) · Mental Disorders (19) · Disruptive, Impulse Control, and Conduct Disorders (18) · Chemically-Induced Disorders (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · Infections (3) · Lentivirus Infections (3) · RNA Virus Infections (3) · Retroviridae Infections (3) · Sexually Transmitted Diseases, Viral (3)
Cognitive Behavioral Therapy (2) · Naloxone (2) · Naltrexone (2) · Sugars (2) · Acetylcysteine (1) · Dextroamphetamine (1) · Fluphenazine (1) · Haloperidol (1) · Lactose (1) · Memantine (1) · Psilocybin (1) · Psychotherapy, Group (1) · Secondary Prevention (1) · Sertraline (1) · Silymarin (1)
Centers for Disease Control and Prevention (3) · University of Chicago (3) · Centre for Addiction and Mental Health (2) · Finnish Institute for Health and Welfare (2) · University of Sao Paulo (2) · University of Washington (2) · Yale University (2) · Colchester East Hants Health Authority (1) · Emalex Biosciences Inc. (1) · Nantes University Hospital (1) · New York State Psychiatric Institute (1) · Pro-Change Behavior Systems (1) · Somaxon Pharmaceuticals (1) · University of Miami (1) · University of Minnesota (1)
United States (14) · Canada (3) · Finland (2) · Brazil (1) · France (1)
Jeffrey H Herbst, PhD (3) · Thomas M Painter, PhD (3) · Hannu Alho, Prof. (2) · Jon E Grant, MD, JD (2) · Jon E Grant, MD, JD, MPH (2) · Carlos Blanco, M.D. (1) · Daniel A. Santisteban, Ph.D. (1) · Daniela Lobo, MD, Ph.D. (1) · David Hodgins, PhD (1) · David W Springer, PhD (1) · Dazon Dixon Diallo, MPH (1) · Deborah A Levesque, Ph.D. (1) · Donald Black, MD (1) · Greg Purvis, MSc (1)
PMID 36130734, PMID 19267264, PMID 20135214, PMID 20721537, PMID 22188239, PMID 23586456, PMID 23953269, PMID 24345329, PMID 24743662, PMID 24743663, PMID 25166480, PMID 35751944, PMID 36919514, PMID 38478366
1RC1DA028279-01 (1), 2017 (1), 2025 (1), K23DA000482 (1), K23MH069754 (1), R01DA027920 (1), R01HD078163 (1), R21MH067026 (1)